Cartesian Therapeutics EBITDA 2015-2025 | RNAC

Cartesian Therapeutics ebitda from 2015 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Cartesian Therapeutics EBITDA 2015-2025 | RNAC

Cartesian Therapeutics ebitda from 2015 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.4B
Amgen (AMGN)$157.5B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100B
Bristol Myers Squibb (BMY)$98.1B
CSL (CSLLY)$85.5B
GSK (GSK)$79.6B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$59.9B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26.9B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19.9B
Incyte (INCY)$16.6B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
Moderna (MRNA)$10.9B
QIAGEN (QGEN)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.1B
Roivant Sciences (ROIV)$8B